3 completed, 2 unknown, 1 suspended, 1 terminated. 3 Phase 1, 3 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 1, Terminated 1, Unknown 1 |
| Phase 2 | 3 | Completed 1, Suspended 1, Unknown 1 |
| Phase 3 | 3 | Completed 1, Suspended 1, Unknown 1 |
Follow talactoferrin alfa: new trials by email Literature Review of talactoferrin alfa trials Research Report on talactoferrin alfa
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer talactoferrin, laboratory biomarker analysis - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 1 | Terminated | Stanford University | 4 | 2012-05-01 | 2016-08-02 |
| Safety and Efficacy of Talactoferrin Alfa in Patients With Severe Sepsis Talactoferrin alfa, Placebo - Severe Sepsis | Phase 2 / Phase 3 | Suspended | Agennix | 1280 | 2011-06-01 | 2012-02-03 |
| Study of Talactoferrin Oral Solution for Nosocomial Infection in Preterm Infants Talactoferrin, Placebo - Nosocomial Infections | Phase 1 / Phase 2 | Unknown | Agennix | 120 | 2009-06-01 | 2012-03-15 |
| Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer Talactoferrin, Placebo - Non Small Cell Lung Cancer | Phase 3 | Unknown | Agennix | 1100 | 2009-02-01 | 2012-03-15 |
| Safety and Efficacy of Talactoferrin in Previously Treated Patients With Non-small Cell Lung Cancer Talactoferrin, Placebo - Non Small Cell Lung Cancer | Phase 3 | Completed | Agennix | 742 | 2008-11-01 | 2012-08-21 |
| Effect of Talactoferrin in Adults With Non-Small Cell Lung Cancer Talactoferrin, Apheresis - Non-Small Cell Lung Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 10 | 2008-06-19 | 2018-07-05 |
| Safety and Efficacy Study of Recombinant Human Lactoferrin to Treat Severe Sepsis Talactoferrin alfa, Placebo - Severe Sepsis | Phase 2 | Completed | Agennix | 190 | 2008-04-01 | 2011-08-23 |
Carcinoma, Non-Small-Cell Lung (4) · Sepsis (2) · Cross Infection (1) · Lung Neoplasms (1) · Salivary Gland Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1) · Tongue Neoplasms (1)
Agennix (5) · National Cancer Institute (NCI) (1) · Stanford University (1)
United States (7) · Canada (3) · France (3) · Germany (3) · Spain (3) · United Kingdom (2) · Australia (1) · Belgium (1) · Bulgaria (1) · Czechia (1) · Denmark (1) · Greece (1) · Hungary (1) · India (1) · Israel (1)
Heather Wakelee (1) · James L Gulley, M.D. (1) · Kalpalatha K Guntupalli, MD (1)
PMID 23425819, PMID 26010687, PMID 27234409, PMID 27260839
R44HD057744 (1)